ClinicalTrials.gg
CompletedNCT00413036Updated Mar 1, 2017Results posted

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

A Phase 2 interventional study of lenalidomide in Lymphoma, Non-Hodgkin's, sponsored by Celgene. Completed at 53 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin — 2 open to participants now, 4 under way, 1 of them phase 3. Lenalidomide · Lymphoma, Non-Hodgkin.

Enrollment
4th of 31
217 · median 46
Started
2006
the only one that year
Phase 2
11 of 32
1 open now
Registered
4th of 32
by date
Lead sponsor
8 of 32
Celgene

Among the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2006, is one of 11 in phase 2, and was the 4th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop

03

Conditions studied

  • Lymphoma, Non-Hodgkin's

Keywords

  • Celgene
  • Revlimid
  • CC-5013
  • Non-hodgkin's lymphoma
  • Lenalidomide
  • CC5013
  • NHL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria

  • proven aggressive non-hodgkin's lymphoma

    • Follicular center lymphoma Grade 3.
    • Diffuse large B-cell lymphoma.
    • Mantle cell lymphoma.
    • Transformed lymphoma.
  • to previous therapy for lymphoma
  • At least one prior combination chemotherapy regime
  • on cross sectional imaging that is at least 2 cm in the longest diameter
  • (ECOG) performance score of 0, 1 or 2
  • Willing to follow the pregnancy precautions

Key Exclusion criteria

  • Any of the following laboratory abnormalities.

    • (ANC) \< 1,500 cells/mm\^3 (1.5*10\^9/L).
    • count \< 60,000/mm\^3 (60*10\^9/L).
    • Calculated of \<50mL/min
    • Serum glutamic oxaloacetic transaminase/ (SGOT/AST) or Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times (ULN).
    • Serum total > 2.0 mg/dL (34 µmol/L)/conjugated bilirubin >0.8mg/dL.
  • Subjects who are candidates for and willing to undergo an stem cell transplant.
  • History of active Central Nervous System (CNS) lymphoma within the previous 6 months
  • History of other within the past year
  • Positive (HIV) or active or C
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    lenalidomide

    25 mg oral lenalidomide once daily on Days 1-21 every 28 days

    Drug: lenalidomide

Interventions

  • once daily oral capsule

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Participants Categorized by Best Response as Determined by Central Review

    Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definitions, refer to Cheson article. * Complete Response(CR): Complete disappearance of all detectable disease and disease-related symptoms if present before therapy; normalization of lab abnormalities assignable to NHL. If bone marrow involved before treatment, must be cleared on repeat biopsy. * Complete Response Unconfirmed(CRu): CR, with one of the following: 1)residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters(SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2)indeterminate bone marrow. * Partial Response(PR): \>50% decrease in 6 largest nodes or nodal masses. Nodes selected according to Cheson. * Stable Disease(SD): Less than PR, but not progressive disease. * Progressive Disease(PD): Appearance of new lesion during/end of therapy; \>=50% increase from lowest measurement in SPD.

    Time frame: Up to 1459 days

Secondary outcomes

  1. Duration of Response as Determined by Central Review

    Kaplan-Meier estimates for the duration of response were calculated for responders and defined as the time from at least a partial response (PR) to progression of disease (PD) or death due to Non-Hodgkin's lymphoma. For response assessment criteria (per Cheson, 1999) see the primary outcome measure in this results posting.

    Time frame: Up to 1459 days

  2. Time to Progression as Determined by Central Review

    Kaplan-Meier estimate of time-to-progression is calculated as time from the start of study drug therapy to the first observation of disease progression. Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definition of progressive disease, refer to Cheson article. * Progressive Disease(PD): Appearance of new lesion during/end of therapy; \>=50% increase from lowest measurement in SPD.

    Time frame: Up to 1459 days

  3. Progression-free Survival as Determined by Central Review

    Kaplan-Meier estimate of progression-free survival is defined as start of study drug therapy to the first observation of progressive disease or death due to any cause, whichever comes first. Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definition of progressive disease, refer to Cheson article. * Progressive Disease(PD): Appearance of new lesion during/end of therapy; \>=50% increase from lowest measurement in SPD.

    Time frame: Up to 1459 days

  4. Proportion of Participants Who Experienced Stable Disease or Better as Determined by Central Review

    Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definitions, refer to Cheson article. * Complete Response(CR): Complete disappearance of all detectable disease and disease-related symptoms if present before therapy; normalization of lab abnormalities assignable to NHL. If bone marrow involved before treatment, must be cleared on repeat biopsy. * Complete Response Unconfirmed(CRu): CR, with one of the following: 1)residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters(SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2)indeterminate bone marrow. * Partial Response(PR): \>50% decrease in 6 largest nodes or nodal masses. Nodes selected according to Cheson. * Stable Disease(SD): Less than PR, but not progressive disease.

    Time frame: Up to 1459 days

07

Results

Posted Apr 11, 2013

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide
Started217
Completed0
Not completed217
Withdrew: Adverse event44
Withdrew: Lack of efficacy129
Withdrew: Withdrawal by subject7
Withdrew: Death9
Withdrew: Other26
Withdrew: Missing2

Outcome measures

PrimaryParticipants Categorized by Best Response as Determined by Central Review

Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definitions, refer to Cheson article. * Complete Response(CR): Complete disappearance of all detectable disease and disease-related symptoms if present before therapy; normalization of lab abnormalities assignable to NHL. If bone marrow involved before treatment, must be cleared on repeat biopsy. * Complete Response Unconfirmed(CRu): CR, with one of the following: 1)residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters(SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2)indeterminate bone marrow. * Partial Response(PR): \>50% decrease in 6 largest nodes or nodal masses. Nodes selected according to Cheson. * Stable Disease(SD): Less than PR, but not progressive disease. * Progressive Disease(PD): Appearance of new lesion during/end of therapy; \>=50% increase from lowest measurement in SPD.

Time frame:
Up to 1459 days
Reported as:
Number · Participants
Participants Categorized by Best Response as Determined by Central Review
ParticipantsLenalidomide
Complete Response (CR)7
Complete Response Unconfirmed (CRu)21
Partial Response (PR)40
Stable Disease (SD)71
Progressive Disease78
SecondaryDuration of Response as Determined by Central Review

Kaplan-Meier estimates for the duration of response were calculated for responders and defined as the time from at least a partial response (PR) to progression of disease (PD) or death due to Non-Hodgkin's lymphoma. For response assessment criteria (per Cheson, 1999) see the primary outcome measure in this results posting.

Time frame:
Up to 1459 days
Reported as:
Median · Months
Duration of Response as Determined by Central Review
MonthsLenalidomide
Duration of Response as Determined by Central Review18.4 (6.51 to 34.06)
SecondaryTime to Progression as Determined by Central Review

Kaplan-Meier estimate of time-to-progression is calculated as time from the start of study drug therapy to the first observation of disease progression. Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definition of progressive disease, refer to Cheson article. * Progressive Disease(PD): Appearance of new lesion during/end of therapy; \>=50% increase from lowest measurement in SPD.

Time frame:
Up to 1459 days
Reported as:
Median · Months
Time to Progression as Determined by Central Review
MonthsLenalidomide
Time to Progression as Determined by Central Review4.5 (3.68 to 6.28)
SecondaryProgression-free Survival as Determined by Central Review

Kaplan-Meier estimate of progression-free survival is defined as start of study drug therapy to the first observation of progressive disease or death due to any cause, whichever comes first. Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definition of progressive disease, refer to Cheson article. * Progressive Disease(PD): Appearance of new lesion during/end of therapy; \>=50% increase from lowest measurement in SPD.

Time frame:
Up to 1459 days
Reported as:
Median · Months
Progression-free Survival as Determined by Central Review
MonthsLenalidomide
Progression-free Survival as Determined by Central Review4.5 (3.68 to 6.28)
SecondaryProportion of Participants Who Experienced Stable Disease or Better as Determined by Central Review

Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definitions, refer to Cheson article. * Complete Response(CR): Complete disappearance of all detectable disease and disease-related symptoms if present before therapy; normalization of lab abnormalities assignable to NHL. If bone marrow involved before treatment, must be cleared on repeat biopsy. * Complete Response Unconfirmed(CRu): CR, with one of the following: 1)residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters(SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2)indeterminate bone marrow. * Partial Response(PR): \>50% decrease in 6 largest nodes or nodal masses. Nodes selected according to Cheson. * Stable Disease(SD): Less than PR, but not progressive disease.

Time frame:
Up to 1459 days

No measurements were reported for this outcome.

Adverse events

Collected over Up to 1459 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—102/217 (47%)188/217 (86.6%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventLenalidomide
PyrexiaGeneral disorders12/217
NeutropeniaBlood and lymphatic system disorders11/217
PneumoniaInfections and infestations9/217
General Physical Health DeteriorationGeneral disorders8/217
Pleural EffusionRespiratory, thoracic and mediastinal disorders8/217
AstheniaGeneral disorders7/217
DyspnoeaRespiratory, thoracic and mediastinal disorders6/217
AnaemiaBlood and lymphatic system disorders6/217
Febrile NeutropeniaBlood and lymphatic system disorders6/217
Non-Hodgkin's LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/217
Most frequent other events
Showing 10 of 19
Most frequent other events
EventLenalidomide
FatigueGeneral disorders25/217
ConstipationGastrointestinal disorders22/217
NeutropeniaBlood and lymphatic system disorders22/217
RashSkin and subcutaneous tissue disorders20/217
NauseaGastrointestinal disorders18/217
AnaemiaBlood and lymphatic system disorders18/217
ThrombocytopeniaBlood and lymphatic system disorders17/217
CoughRespiratory, thoracic and mediastinal disorders16/217
Muscle spasmsMusculoskeletal and connective tissue disorders15/217
White Blood Cell Count DecreasedInvestigations15/217

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide
Mean65.0 ± 11.54
Age, Customized
Age, Customized(Participants)Lenalidomide
< 65 years90
> = 65 years127
Gender
Gender(Participants)Lenalidomide
Female77
Male140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participant)Lenalidomide
American Indian or Alaska Native0
Asian/Pacific Islander0
Black4
Hispanic2
White202
Unspecified9
Non-Hodgkin's Lymphoma Diagnosis/Histopathology
Non-Hodgkin's Lymphoma Diagnosis/Histopathology(Participants)Lenalidomide
Diffuse Large Cell Lymphoma108
Follicular Lymphoma, Grade 319
Mantle Cell Lymphoma57
Transformed Lymphoma33
08

Study locations

53 sites
  • Northwest Alabama Cancer Center, PC
    Muscle Shoals, Alabama 35661, United States
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Lalita Pandit, MD, Inc
    Fountain Valley, California 92708, United States
  • Access Clinical Research
    Rancho Mirage, California 92270, United States
  • Kaiser Permanente Medical Group
    San Diego, California 92120, United States
  • Pasco Hernando Oncology Associates
    Brooksville, Florida 34613, United States
  • Sylvester Cancer Center/ Univeristy of Miami
    Miami, Florida 33136, United States
  • Hematology Oncology Associates of Central Brevard
    Rockledge, Florida 32955, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Cancer Care Center, Inc.
    New Albany, Indiana 47150, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70809, United States
  • Michigan Hematology and Oncology Institute
    Southgate, Michigan 48195, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Nebraska
    Omaha, Nebraska 68198, United States
  • Center for Cancer and Hematologic Disease
    Cherry Hill, New Jersey 08003, United States
  • Our Lady of Mercy Cancer Center
    Bronx, New York 10466, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • HIllman Cancer Center -UPMC
    Pittsburg, Pennsylvania 15232, United States
  • Palmetto Hematology Oncology
    Spartanburg, South Carolina 29303, United States
  • Family Cancer Center
    Collierville, Tennessee 38017, United States
  • London Health Science Center
    London, Ontario, Canada
  • Saskatoon Cancer Center
    Saskatoon, Saskatchewan, Canada
  • Toronto Sunnybrook Regional Cancer Centre
    Toronto, M4N 3M5, Canada
  • Service d'Hématologie Clinique
    Créteil, 94010, France
  • Clinical Haematology Department
    Dijon, 21034, France
  • Institute Paoli-Calmettes Départmentd 'Hématologie
    Marseille, 13273, France
  • CHU Hopital Lapeyronie, Hematologie et Oncologie Medicale
    Montpellier, 34295, France
  • Hopital Saint Louis Service d'Hémato-Oncologie
    Paris, 75 475, France
  • Hopital du Haut-Lévèque
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud, Hematologie Clinique
    Pierre Bénite, 69310, France
  • Department d'Hématologie Centre Henri Becquerel
    Rouen, 76 038, France
  • Research Site
    Berlin, Germany
  • Universitaetsklinikum Essen
    Essen, 45122, Germany
  • Research Site
    Goettingen, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Homburg, Germany
  • Research Site
    Koeln, Germany
  • Institute of Hematology and Medical Oncology "L. & A. Seràgnoli"
    Bologna, 40138, Italy
  • O.U. di Clinica Ematologica
    Genova, 16132, Italy
  • Ospedale Policlinico S. Matteo
    Pavia, 27100, Italy
  • Dipartimento di Oncologia dei Trapianti e delle Nuove Tecnologie in Medicina
    Roma, 56127, Italy
  • Azienda Sanitaria Ospedaliera San Giovanni Battista (Molinette),
    Torino, 10126, Italy
  • Hospital Clinic I Provincial, Servicio de Hematologia
    Barcelona, 08036, Spain
  • Hospital Clinicio San Carlos, Servivio de Hematologia Clinica
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre,
    Madrid, 28041, Spain
  • Hospital Universitario Virgen de la Victoria, Servicio de oncologia
    Malaga, 29010, Spain
  • Clinica Universitaria de Navarra
    Pamplona, 31008, Spain
  • Complexo Hospitalario de Pontevedra Oncology Department
    Pontevedra, 36001, Spain
  • Hospital Clinico Universitario de Salamanca, Servicio de Hematologia
    Salamanca, 37007, Spain
  • Research Site
    Valencia, Spain
  • Somers Cancer Research Building
    Southampton, SO16 6YD, United Kingdom
  • Royal Marsden Hospital NHS Foundation Trust London and Surrey
    Surrey, SM2 5PT, United Kingdom
  • Medical Oncology, Christie Hospital NHS Trust
    Withington, M20 4BX, United Kingdom
09

References and documents

Publications

  • Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, Tilly H, Zhang L, Prandi K, Li J, Witzig TE. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013 Nov;24(11):2892-7. doi: 10.1093/annonc/mdt366. Epub 2013 Sep 12. PubMed 24030098 ↗
  • Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011 Jul;22(7):1622-1627. doi: 10.1093/annonc/mdq626. Epub 2011 Jan 12. PubMed 21228334 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Apr 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2006
First posted
Dec 19, 2006
Start
Jun 2006
Primary completionActual
Apr 2011
CompletionActual
May 2011
Results first posted
Apr 11, 2013
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00413036
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 19, 2006
Start date
Jun 2006
Primary completion
Apr 2011
Completion
May 2011
Results posted
Apr 11, 2013
Last update
Mar 1, 2017

Study contacts

Lei Zhang, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion